HTA Council Recommendation (as of 16 June 2021) As final recommendation, the HTA Council does not recommend the inclusion of lapatinib [250 mg tablet] for the treatment of HER2-positive breast cancer in the Philippine National Formulary (PNF). Relevant Information Evidence and Relevant Documents Assessment History Back to Assessments Page
Insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
HTA Council Recommendation (as of 03 October 2022) As final recommendation, the HTA Council recommends the government financing and inclusion of insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Philippine National Formulary (PNF). Relevant Information Evidence and Relevant Documents continue reading : Insulin glargine [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
HTA Council Recommendation (as of 03 October 2022) As final recommendation, the HTA Council does not recommend the government financing and inclusion of insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM) in the Philippine National Formulary (PNF). Relevant Information Evidence and continue reading : Insulin detemir [100 U/mL solution for injection] for the treatment of Type 1 Diabetes Mellitus (T1DM) and Type 2 Diabetes Mellitus (T2DM)
Rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation
HTA Council Recommendation (as of 18 April 2023) The HTA Council recommends the government financing of dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients through their inclusion in the PNF. Relevant Information continue reading : Rivaroxaban [15 mg and 20 mg film-coated tablet] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation
Dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients
HTA Council Recommendation (as of 18 April 2023) The HTA Council recommends the government financing of dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients through their inclusion in the PNF. Relevant Information continue reading : Dabigatran [110 mg and 150 mg capsule] for the prevention of myocardial infarction, cerebrovascular disease, and other cardiovascular events among patients with nonvalvular atrial fibrillation (NVAF) and subgroup of NVAF patients